Merck & Co. Inc
6MK.F
| Exchange: | F |
| Currency | Euro |
| ISIN: | US58933Y1055 |
| LEI: | MZK1AT00SJV4XB7WNL71 |
| Primary Ticker: | MRK.US |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Drug Manufacturers - General |
| Gic Sector: | Health Care |
| Gic Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry: | Pharmaceuticals |
| Gic Sub Industry: | Pharmaceuticals |
| Description: | Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, Pro Quad, M-M-R II, Varivax, Rota Teq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and Astra Zeneca PLC to co-development and co-commercialize Astra Zeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey. |
| Address: | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 |
| Website: | https://www.merck.com |
| Full Time Employees: | 70000 |
| Updated On: | 2024-11-03 |
Highlights
| Market Capitalization: | 239286075392 |
| Market Capitalization Mln: | 239286.07 |
| EBITDA: | 31673999360 |
| PE Ratio: | 21.50 |
| PEG Ratio: | 0.06 |
| Book Value: | 17.18 |
| Dividend Share: | 3.04 |
| Dividend Yield: | 0.02 |
| Earnings Share: | 4.39 |
| Most Recent Quarter: | 2024-06-30 |
| Profit Margin: | 0.19 |
| Operating Margin TTM: | 0.26 |
| Return On Assets TTM: | 0.11 |
| Return On Equity TTM: | 0.33 |
| Revenue TTM: | 63174000640 |
| Revenue Per Share TTM: | 24.94 |
| Quarterly Revenue Growth YOY: | 0.04 |
| Gross Profit TTM: | 42077000000 |
| Diluted Eps TTM: | 4.39 |
| Quarterly Earnings Growth YOY: | -0.33 |
Valuation
| Trailing PE: | 21.50 |
| Forward PE: | 10.24 |
| Price Sales TTM: | 3.78 |
| Price Book MRQ: | 5.97 |
| Enterprise Value: | 261558632834 |
| Enterprise Value Revenue: | 4.50 |
| Enterprise Value Ebitda: | 20.13 |
Shares
| Shares Outstanding: | 2534810112 |
| Shares Float: | 2530297351 |
| Percent Insiders: | 0.05 |
| Percent Institutions: | 79.34 |
Technicals
| Beta: | 0.39 |
| 52 Week High: | 124.08 |
| 52 Week Low: | 88.14 |
| 50 Day MA: | 102.11 |
| 200 Day MA: | 112.48 |
Splits & Dividends
| Forward Annual Dividend Rate: | 2.8 |
| Forward Annual Dividend Yield: | 0.02 |
| Payout Ratio: | 0.64 |
| Ex Dividend Date: | 2024-09-16 |
Earnings
| Report Date: | 2025-10-30 |
| Date: | 2025-09-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2025-07-29 |
| Date: | 2025-06-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2025-04-24 |
| Date: | 2025-03-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2025-02-04 |
| Date: | 2024-12-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2024-10-31 |
| Date: | 2024-09-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2024-07-30 |
| Date: | 2024-06-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Date: | 2024-09-30 |